Myopic macular degeneration Market: Epidemiology, Therapies, Companies, DelveInsight | Bayer/Regeneron Pharmaceuticals, Roche

Myopic macular degeneration therapies, such as EYLEA (aflibercept), VABYSMO (faricimab), and others, are expected to boost the Myopic macular degeneration Market in the upcoming years.

DelveInsight has launched a new report on "Myopic macular degeneration - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Myopic macular degeneration, historical and forecasted epidemiology as well as the Myopic macular degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Myopic macular degeneration market report @ https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Myopic macular degeneration Market Report:

In the 7MM, the Myopic Macular Degeneration (MMD) market in 2022 was primarily driven by anti-VEGF treatments and standard care practices, generating around USD 734 million. Growth in this market is expected to be gradual through the forecast period (2023-2034), largely due to a limited pipeline of emerging therapies.
According to DelveInsight, Japan held the largest share of diagnosed MMD cases in the 7MM, accounting for 49% of the total. The United States followed, contributing roughly 27% of diagnosed cases in 2022.
Epidemiological data suggests that Myopic Macular Degeneration disproportionately affects females across the 7MM, a trend that may be influenced by hormonal, genetic, or environmental factors.
Choroidal neovascularization (CNV), a serious complication of pathological myopia, represented 5% of all diagnosed MMD cases in the 7MM in 2022.
Key pharmaceutical companies such as Roche, Bayer, and Regeneron Pharmaceuticals are actively developing novel treatments aimed at addressing existing gaps in care and enhancing outcomes for patients with MMD globally.
According to DelveInsight's estimates, the total number of diagnosed cases of Myopic Macular Degeneration across the 7MM was around 4.1 million in 2022, with expectations for this number to rise during the forecast period. In the United States, approximately 1.1 million people were diagnosed with Myopic Macular Degeneration in 2022, and this figure is projected to grow at an estimated compound annual growth rate (CAGR) throughout the study period from 2020 to 2034.
In 2024, the U.S. Food and Drug Administration (FDA) approved several treatments for MMD:
Byooviz (ranibizumab-nuna): This biosimilar to Lucentis is approved for various retinal conditions, including myopic choroidal neovascularization (mCNV), a complication of MMD.

Cimerli (ranibizumab-eqrn): Another biosimilar to Lucentis, Cimerli is indicated for mCNV and offers a cost-effective alternative for patient.

Susvimo (ranibizumab injection): This implantable device delivers ranibizumab continuously over six months, reducing the frequency of injections for patients with wet age-related macular degeneration and mCNV.
Key Myopic macular degeneration companies such as Bayer/Regeneron Pharmaceuticals, Roche, and others are evaluating new drugs for Myopic macular degeneration to improve the treatment landscape.
Promising Myopic macular degeneration therapies include EYLEA (aflibercept), VABYSMO (faricimab), and others.

Myopic macular degeneration Overview

Myopia is a refractive error where objects in the distance appear blurry, while nearby objects are clearer. High myopia refers to a more severe form of nearsightedness. People with high myopia are at a higher risk of developing vision-threatening complications, including myopic macular degeneration, posterior staphyloma, and retinal detachment, all of which can lead to permanent vision loss.

The progression from myopia to pathological myopia creates conditions for several eye complications, one of which is Myopic Macular Degeneration. This condition involves the gradual breakdown of the macula, the central part of the retina responsible for sharp vision. The elongation of the eyeball, thinning of the choroid, and changes in retinal structure make the macula more susceptible to damage, leading to Myopic Macular Degeneration. This is marked by staphyloma, lacquer cracks, Fuchs' spot, or chorio-retinal atrophy in the posterior pole.

Myopic macular degeneration Market Outlook

Myopic maculopathy, also known as Myopic Macular Degeneration or myopic retinopathy, includes conditions like macular atrophy, lacquer cracks, and choroidal neovascularization (mCNV), and is influenced by factors such as age and axial length. Approaches like low-concentration atropine and optical treatments are used to slow myopic progression.

Currently, there is no treatment for myopic maculopathy, except for managing mCNV, highlighting the urgent need for additional treatment options. Existing therapies for Myopic Macular Degeneration are based on wet AMD treatments, using anti-VEGF drugs such as LUCENTIS (whose patent has expired) and EYLEA.

Discover how the Myopic macular degeneration market is rising in the coming years @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Myopic Macular Degeneration Marketed Drugs
EYLEA (aflibercept): Bayer/Regeneron Pharmaceuticals
Myopic macular degeneration Emerging Drugs
VABYSMO (faricimab): Roche

Scope of the Myopic macular degeneration Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Myopic macular degeneration Companies: Bayer/Regeneron Pharmaceuticals, Roche, and others
Key Myopic macular degeneration Therapies: EYLEA (aflibercept), VABYSMO (faricimab), and others
Myopic macular degeneration Therapeutic Assessment: Myopic macular degeneration current marketed and Myopic macular degeneration emerging therapies
Myopic macular degeneration Market Dynamics: Myopic macular degeneration market drivers and Myopic macular degeneration market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Myopic macular degeneration Unmet Needs, KOL's views, Analyst's views, Myopic macular degeneration Market Access and Reimbursement

To know what's more in our Myopic macular degeneration report, visit https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Myopic macular degeneration Market Report:
Myopic macular degeneration market report covers a descriptive overview and comprehensive insight of the Myopic macular degeneration Epidemiology and Myopic macular degeneration market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Myopic macular degeneration market report provides insights into the current and emerging therapies.
The Myopic macular degeneration market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Myopic macular degeneration market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myopic macular degeneration market.

Got queries? Click here to know more about the Myopic macular degeneration market Landscape https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Myopic macular degeneration Patient Share (%) Overview at a Glance
5. Myopic macular degeneration Market Overview at a Glance
6. Myopic macular degeneration Disease Background and Overview
7. Myopic macular degeneration Epidemiology and Patient Population
8. Country-Specific Patient Population of Myopic macular degeneration
9. Myopic macular degeneration Current Treatment and Medical Practices
10. Unmet Needs
11. Myopic macular degeneration Emerging Therapies
12. Myopic macular degeneration Market Outlook
13. Country-Wise Myopic macular degeneration Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Myopic macular degeneration Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Myopic macular degeneration Market Outlook 2034 https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Myopic macular degeneration Pipeline Insights, DelveInsight

"Myopic macular degeneration Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myopic macular degeneration market. A detailed picture of the Myopic macular degeneration pipeline landscape is provided, which includes the disease overview and Myopic macular degeneration treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.